Genevation is an preclinical biotech startup pioneering the development of personalized cancer vaccines using cutting-edge mRNA technology and AI-driven neoantigen identification. Our mission is to revolutionize cancer treatment by creating highly effective, patient-specific vaccines. Our proprietary cancer panel and advanced AI systems identify unique neoantigens from individual tumors, ensuring precise targeting and enhanced therapeutic outcomes. With a strong commitment to innovation, we have developed a cell-free mRNA vaccine delivery platform and advanced purification processes, setting new standards in stability, efficacy, and cost-effectiveness. Our preclinical trials data will be available soon in skin, lung, and colon cancers. We are expanding our global presence, including a subsidiary in the USA, and collaborating with top-tier research institutions and healthcare providers to accelerate clinical development. Our ultimate goal is to provide accessible, personalized cancer vaccines that significantly improve patient outcomes and quality of life. Through strategic partnerships, robust R&D, and a patient-centered approach, we aim to transform the cancer treatment landscape, offering hope and innovative solutions to millions of cancer patients worldwide.